

Case Report on Ayurveda management of Polysystic Ovarian Syndrome
(PCOS)Patel R^{1*}, Shaikh N²

DOI:10.21760/jaims.10.7.59

^{1*} Riya Patel, Student of SRPT Master Course, JS Ayurved Mahavidyalaya, Nadiad, Gujarat, India.² Nilofar Shaikh, Associate Professor, Department of Stri Roga and Prasuti Tantra, JS Ayurved Mahavidyalaya, Nadiad, Gujarat, India.

Polycystic Ovarian Syndrome (PCOS) is common problem among the reproductive age (18-40 years) of women. It is endocrine and gynecology problem. PCOD become lifestyle disorder now a day's because of sedentary habits, eating fast food, follow faulty life style. The exact cause of PCOS is unknown but high level of insulin, hyper androgen (male hormone), LH (luteinizing hormone) are the main causes. The symptoms of PCOS are delayed menstruation, oligomenorrhea, acne, hirsutism, thinning of hair, obesity, and constipation. In Ayurveda PCOS is not direct term coined but clinically it is resembled with Aartavavaha Sroto Dushti, Aartava Kshaya and Beejashaya Granthi. A case of 17 year old female patient with complains of no menstruation since 4 months and acne on face was attended OPD of Prasuitantra evam Streeroga department of J.S Ayurveda Mahavidyalaya. She had her first menstruation at age of 16 year. Patient was successfully treated by various Ayurveda medicines and Nasya therapy at OPD of Prasuitantra Evam Streeroga Department of JS Ayurveda Mahavidyalaya. Patient got significant relief in delay menstruation and had mild relief in acne on face after the 3 months of Ayurveda treatment. Her USG report suggested volume reduction in bilateral ovaries also.

Keywords: Ayurveda, PCOS, Nasyakarma, Shatapushapa Taila, Kanchanar Guggulu, Artavakshaya

Corresponding Author	How to Cite this Article	To Browse
Riya Patel, Student of SRPT Master Course, , JS Ayurved Mahavidyalaya, Nadiad, Gujarat, India. Email: riyabpatel204@gmail.com	Patel R, Shaikh N, Case Report on Ayurveda management of Polysystic Ovarian Syndrome (PCOS). J Ayu Int Med Sci. 2025;10(7):376-381. Available From https://jaims.in/jaims/article/view/4072/	

Manuscript Received
2025-05-17Review Round 1
2025-05-27Review Round 2
2025-06-07Review Round 3
2025-06-17Accepted
2025-06-26Conflict of Interest
NoneFunding
NilEthical Approval
Not requiredPlagiarism X-checker
12.96

Note

© 2025 by Patel R, Shaikh N and Published by Maharshi Charaka Ayurveda Organization. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License <https://creativecommons.org/licenses/by/4.0/> unported [CC BY 4.0].

Introduction

Polycystic ovary syndrome (PCOS) was originally delineated in 1935 by Leventhal and Stein.[1] PCOS is one of the most common endocrine disorder of women in their reproductive period manifested by irregular menstrual cycle and polycystic ovaries; excess unwanted hair and baldness, although not all patient have all these features. The term 'polycystic' means 'many cysts' and PCOS gets its name because of the clusters of small, pearl size cysts in ovaries. These cysts are fluid filled bubble (called follicle) that contains eggs that have not yet been released because of the hormonal imbalance. Many women with PCOS demonstrate challenges of feminine identity and body image due to obesity, acne and excess of unwanted hair; also infertility and long-term health related concerns that compromise the quality of life and adversely affect mood and psychological well-being.

PCOS is a heterogeneous endocrine disorder that affects about 5% of women worldwide.[2] The prevalence is 9% and average age of onset of depression is 31.9 year in Nepal.[3] Up to 40% of women with PCOS develop either impaired glucose tolerance of type 2 diabetes by age of 40.[4] Large amount of testosterone is secreted in PCOS which possibly prevent ovaries from releasing an egg each month, thus causing infertility, which may be the result of high levels of insulin that stimulate ovaries to produce excess testosterone. High testosterone levels can also cause excessive hair growth, stimulating male pattern baldness and acne. In patient with PCOS, insulin resistance causes fat deposition and excessive production of testosterone. [5]

The cause of PCOS is unknown, but studies suggest a strong genetic component that is affected by gestational environment, lifestyle factor or both. Women who have PCOS are at an increased risk of cardiovascular disease, diabetes and pre-diabetes, endocrinal cancer, heart attack, hypertension, high level of low density lipoprotein and low levels of high density lipoprotein.[6]

In *Ayurvedic* classics there is no direct mentioning of this disease rather, symptoms are found under various diseased conditions at various references i.e., menstrual irregularities are described under broad heading of *Ashtoartavadushti*, while description of infertility due to anovulation is scattered.

Irregular menstruation can be correlated with *Raj-ahkshaya*, *Pushpaghni Jataharini* mentioned in *Kashyapa Samhita*, *Revati Kalpadhyaya* bears similitude to symptoms of hyperandrogenism.[7] But features of metabolic dysfunction and polycystic ovarian morphology are not evident from any description.

Clinical Manifestation

- Hyperandrogenism-characterized by elevated levels of serum androgen.
- Anovulation
- Metabolic disturbances
- 15% of female having irregular menstrual cycles
- Chronic anovulation
- Hyperinsulinemia and decreased of SHBG.
- Infertility: Due to chronic anovulation
- Menstrual disorders: PCOS mostly produces oligomenorrhea or amenorrhea
- Weight gain and obesity
- Male pattern baldness

Pathophysiology

Several theories have been proposed to explain the pathogenesis of PCOS:

- Endometrial progesterone resistance
- A unique defect in insulin action and secretion
- A primary neuroendocrine defect leading to an exaggerated ovarian androgen production.
- An alteration in cortisol metabolism resulting in enhanced adrenal androgen production.

Case Report

A diagnosed case 17 year old Hindu female present with no menstruation since 4 month came in OPD of *Streeroga and Prasutitantra* of P.D. Patel *Ayurveda* hospital and J.S. *Ayurveda* Mahavidyalaya Nadiad, Gujarat, India. She had complained of acne on face and constipation since 5 months.

History of past illness

No any significant medical, surgical, gynecological and psychiatric disease.

Family history

No any significant medical, surgical, gynecological and psychiatric disease in her family members.

Personal history

Her appetite was good. She drinks 3-4 glass of water daily. Tongue was mildly coated and dry (*Alpa Sama*).

She passes hard stool and there is constipation. Her bladder habit is normal and she is vegetarian. There is no significant addiction.

Treatment History

For the present illness, patient went to allopathic hospital for treatment, but she didn't find the relief in symptom. So, she visited OPD of *Streeroga* and *Prasutitantra* of P.D Patel Ayurved Hospital, Nadiad.

Menstrual History

Her menarche was late at 16 year, it was irregular menstruation.

Mental state examination

She was normal and cooperative.

Clinical Examination

Built - height - 145cm, weight - 45Kg

Pulse - 76/min; BP - 120/80mm/hg

Systemic examination

No any abnormality was detected in gastro-intestinal, cardio-vascular, nervous and respiratory system examination.

Diagnosis

Diagnosis was done clinically by following symptoms as per Rotterdam criteria.[8]

- Irregular menstrual cycle
- Abnormal menstrual cycle
- Oligomenorrhea
- Poly cystic ovary on USG

According to Ayurveda Samprapti Ghatak:

- **Hetu:** *Divaswapna, Avyayama, Ruksha Ahara Vihara, Abhishyandi Ahara Vihara.*
- **Dosha:** *Kapha, Vata*
- **Dushya:** *Rasa, Meda, Mamsa*
- **Strotas:** *Rasavaha, Medavaha, Artavavaha Strotas.*
- **Pratyatma Lakshana:** *Artavkshaya, Staulya.*

Treatment

1. Nidana Parivarjana

2. First Phase: 15 days

Medicine	Dose
1. Dhatri Lauha	3 tab/3 time with water
2. Rajapravartanvati	2 tab/3 time with water
3. Syp M2 tone	2 tsp/2 time with water

2nd Phase : 15 days

Medicine	Dose	Duration
1. Tab. Dhatri Lauha	3 tab/3 time with water A/F	
2. Tab. Rajapravartani Vati	2 tab /3 time with water A/F	
3. Dashamula Kwatha	10 gm /2 time with water B/F	
4. Tab. Katuki	2 tab /3 time with water A/F	
5. Shatapushpa Churna 2gm + Datamansi Churna 1gm	1 dose/3 time with water A/F	3 months
6. Tab. Kanchanar Guggulu	3 tab/3time with water A/F	
7. Pathadi Kwatha	10 gm/ 2 time B/F	
Nasya Karma		
Shatapushpa Oil	6 drops each nostril for 7 days	3 sitting of Nasya Karma 21 days gap between each sitting.

Pathya-Apathya

- Avoid junk food, cold drinks and packed food/excessive fats/sugar and carbohydrates.
- Avoid plastic packing and used tin container.
- Eat freshly prepared food.
- Walk for 30 min daily at least 5 days per week.
- Includes *Yoga* and *Pranayama* in daily routine.
- Bed time and wake up time should be fixed accordingly and sleep of 6-8 hours is required.

Results and Discussion

After 30 days of treatment her menses comes on regular interval, with normal blood flow. Assessment was done on the basic of following points.

SN	Sign & Symptoms	Day 1	Day 30	Day 60	Day 90
1.	Amount of bleeding	1-2 pad per day	1-3 pad per day	1-3 pad per day	1-3 pad per day
2.	Duration of menses	No menses after 1 time	Menses come	1-2 day	1-3day
3.	Weight	45 kg	42 kg	44kg	44kg
4.	White discharge	++	+	+	-
5.	Facial hair	++	+	+	+
6.	Mood swing	+++	+	+	+

Patient was advised for follow up for 3 months.

Changes in Blood investigation and USG

Before Treatment (15/7/2024)	After Treatment (5/12/2024)
FSH - 5.79 mlu/ml	FSH - 6.32 mlu/ml
LH - 11 mlu/ml	LH - 11.60 mlu/ml
USG Report (15/7/2024)	USG Report (10/9/2024)
Rt. Ovary: 4.3x3.4x2.7cm, vol 19-20 cc	Rt. Ovary: 3.0x1.8x2.3cm, vol 6.6cc
Lt. Ovary: 3.3x3.2x3.0cm, vol 16-17 cc	Lf. Ovary: 3.3x1.8x2.6cm, vol 8.3cc

Unipath
SPECIALTY LABORATORY LTD.
NABL Accredited
ISO 9001:2015 Certified
CN: UB195G200RPLC50709

Unipath House, Beside Sahjanand College, Opposite Kamdhenu Complex, Panjarapole, Ahmedabad-380015, Gujarat
Phone: +91-79-49006800 | WhatsApp: 6356005900 | Email: info@unipath.in | Website: www.unipath.in

TEST REPORT

Reg. No. 4009412968 Date: 15-Jun-2024 19:26 Ref. No. :
Name: [REDACTED] Gender: Female Pass. No.:
Age: 10 years Collected On: 15-Jun-2024 20:44
Ref. By: [REDACTED] Dispatch At: 15-Jun-2024 19:26
Location: MAHAGUJARAT MEDICAL SOCIETY @ NADIAD Tele No.:

Immunosay

Parameter	Result	Units	Biological Reference Interval
Follicle-stimulating Hormone (FSH)	5.79	mIU/mL	Follicular Phase: 3.03-8.08 Mid-Cycle Peak: 2.55 - 16.69 Luteal Phase: 1.38 - 5.47 Postmenopausal Females: 26.72 - 133.41

Useful test as an adjunct in the evaluation of menstrual irregularities. Evaluating patients with suspected hypogonadism. Predicting ovulation. Evaluating infertility. Diagnosing pituitary disorders. FSH and LH are generally elevated in: Primary gonadal failure. Complete testicular feminisation syndrome. Precocious puberty (either idiopathic or secondary to a central nervous system lesion). Menopause (postmenopausal FSH levels are generally >40 IU/L). Primary ovarian hypofunction in females. Primary hypergonadism. Normal or decreased FSH in: Polycystic ovary disease in females. FSH and LH are both decreased in failure of the pituitary or hypothalamus.

This is an electronically authenticated report. Please verify the authenticity of this report by scanning the QR code to ensure data integrity. Test done from collected sample.

Approved by: Dr. Rina Prajapati
D.C.P. DNB (Path)
G-21793
Regd. Office: Unipath Specialty Laboratory Limited - 5th Floor, Doctor House, Nr. Perimal Garden, Ahmedabad-380006 Gujarat

Unipath
SPECIALTY LABORATORY LTD.
NABL Accredited
ISO 9001:2015 Certified
CN: UB195G200RPLC50709

Unipath House, Beside Sahjanand College, Opposite Kamdhenu Complex, Panjarapole, Ahmedabad-380015, Gujarat
Phone: +91-79-49006800 | WhatsApp: 6356005900 | Email: info@unipath.in | Website: www.unipath.in

TEST REPORT

Reg. No. 4009412968 Date: 15-Jun-2024 19:26 Ref. No. :
Name: [REDACTED] Gender: Female Pass. No.:
Age: 10 years Collected On: 15-Jun-2024 20:44
Ref. By: [REDACTED] Dispatch At: 15-Jun-2024 19:26
Location: MAHAGUJARAT MEDICAL SOCIETY @ NADIAD Tele No.:

Immunosay

Parameter	Result	Units	Biological Reference Interval
Luteinizing Hormone (LH)	11.00	mIU/mL	Normal Menstruating Females: Follicular Phase: 1.80 - 11.78 Mid-Cycle Phase: 7.59 - 89.08 Luteal Phase: 0.56 - 14.00 Postmenopausal Females Without HRT: 5.16 - 61.99

Sample Type: Serum

Increased in:

- Primary gonadal failure
- Complete testicular feminisation syndrome
- Precocious puberty

Decreased in:

- Primary hypergonadism
- Failure of pituitary/hypothalamus

End Of Report

This is an electronically authenticated report. Please verify the authenticity of this report by scanning the QR code to ensure data integrity. Test done from collected sample.

Approved by: Dr. Rina Prajapati
D.C.P. DNB (Path)
G-21793
Regd. Office: Unipath Specialty Laboratory Limited - 5th Floor, Doctor House, Nr. Perimal Garden, Ahmedabad-380006 Gujarat

Dr. Ritesh Prajapati
MD, DMRE

X-RAY House
Based on the best of imaging...

Patient Name: [REDACTED] Age: [REDACTED]
Ref. by Dr: [REDACTED] Hospital Study Date: 15 June 2024

ULTRASONOGRAPHY PELVIS:

Urinary bladder is physiologically distended and appears normal. No evidence of stone or S.O.L.

Uterine cervix is normal in size.

Uterus is normal in size, shape and anteverted in position. No evidence of any focal lesion. Endometrium is uniform, central and normal. Endometrial thickness appears normal.

BOTH OVARIES appear mildly enlarged in size and show multiple small peripheral follicles and central echogenic stroma. No evidence of any dominant follicle is seen. No evidence of any adnexal mass lesion is seen.
Right ovary measures: 4.3 x 3.4 x 2.7 cm, vol 19-20 cc.
Left ovary measures: 3.3 x 3.2 x 3.0 cm, vol 16-17 cc.

No free fluid noted in cul de sac.

No evidence of pelvic lymphadenopathy.

IMPRESSION

- Possibility of P.C.O.D.

End of report.

Dr. Ritesh Prajapati MD, DMRE
Dr. Ritesh Prajapati MD, DMRE
Dr. Ritesh Prajapati MD, DMRE
Dr. Ritesh Prajapati MD, DMRE
Dr. Ritesh Prajapati MD, DMRE
Dr. Ritesh Prajapati MD, DMRE
Dr. Ritesh Prajapati MD, DMRE
Dr. Ritesh Prajapati MD, DMRE
Dr. Ritesh Prajapati MD, DMRE
Dr. Ritesh Prajapati MD, DMRE

Before Treatment Reports

MAHAGUJARAT MEDICAL SOCIETY
SHETH H. J. MAHAGUJARAT HOSPITAL
LABORATORY REPORT

Name: [REDACTED] Age: [REDACTED] Gender: Female Lab No: 8582 / 85
Case Type: O Date: 05/12/24

FEMALE REPRODUCTIVE HORMONES ASSAY

INVESTIGATION	RESULT	UNIT	NORMAL VALUE
Follicle Stimulating Hormone - FSH	5.79	mIU/mL	Follicular Phase: 4.5 - 11.0 mIU/mL Ovulatory: 3.6 - 20.6 mIU/mL Luteal Phase: 1.6 - 10.8 mIU/mL Menopause: 30.6 - 108.8 mIU/mL Males: 2.0 - 18.6 mIU/mL Boys: 1.6 - 8.0 mIU/mL Girls: 2.0 - 12.0 mIU/mL
Luteinizing Hormone - LH	11.60	mIU/mL	Follicular Phase: 1.7 - 13.3 mIU/mL Ovulatory: 4.1 - 68.7 mIU/mL Luteal Phase: 0.5 - 19.8 mIU/mL Menopause: 14.4 - 62.2 mIU/mL Males: 1.7 - 11.2 mIU/mL Boys: 0.5 - 4.0 mIU/mL Girls: 1.0 - 7.0 mIU/mL

(Fully Automated Random Access Immunoassay Analyzer)
Model AIA 360 Tosoh Corporation Japan

MR. ATUL SHAH
BIOCHEMIST
06/12/24 10:02:21
DR. RHUTA SHAH
M.D. PATHOLOGY

Dr. Ritesh Prajapati
MD, DMRE

X-RAY House
Based on the best of imaging...

Patient Name: [REDACTED] Age: [REDACTED]
Ref. by Dr: [REDACTED] Hospital Study Date: 10 September 2024

ULTRASONOGRAPHY PELVIS:

Urinary bladder is physiologically distended and appears normal. No evidence of stone or S.O.L.

Uterine cervix is normal in size.

Uterus is normal in size (5.2 x 2.6 x 3.3 cm), shape and anteverted in position. No evidence of any focal lesion. Endometrial thickness appears normal (5.3 mm).

BOTH OVARIES appear normal in size and show multiple small peripheral follicles. No evidence of any dominant follicle is seen. No evidence of any adnexal mass lesion is seen.
Right ovary measures: 3.0 x 3.8 x 2.3 cm, vol: 6.6 cc.
Left ovary measures: 3.3 x 3.8 x 2.6 cm, vol: 8.3 cc.

No free fluid noted in cul de sac.

IMPRESSION:

- Multiple small peripheral follicles in bilateral ovaries, possibility of P.C.O.D. Adv: Hormonal correlation.

End of report.

Dr. Ritesh Prajapati MD, DMRE
Dr. Ritesh Prajapati MD, DMRE
Dr. Ritesh Prajapati MD, DMRE
Dr. Ritesh Prajapati MD, DMRE
Dr. Ritesh Prajapati MD, DMRE
Dr. Ritesh Prajapati MD, DMRE
Dr. Ritesh Prajapati MD, DMRE
Dr. Ritesh Prajapati MD, DMRE
Dr. Ritesh Prajapati MD, DMRE
Dr. Ritesh Prajapati MD, DMRE

After Treatment Reports

Discussion

PCOS is lifestyle disorder. Patient suffering from polycystic ovarian disease have multiple small cysts in their ovaries.

These cysts occur when regular changes of a normal menstrual cycle are disrupted. The ovary is enlarged and produces excessive amounts of androgen and estrogenic hormones. Various drugs that are used in this case are discussed below:

Rajapravartani Vati

Rajapravartanvati has *Katu*, *Tikta*, *Laghu*, *Snighdha* and *Tikshna Guna*, *Katu Vipaka* and *Ushna Virya*. *Tikta Taste* and *Tikshana* properties. This drug will remove the *Srotoavarodha* and facilitates flow of *Vata*; *Katu Vipaka* and *Ushna Virya* pacifies the aggravated *Vata* and thus allow the painless flow of *Artava*.

Dhashamula Kwatha

Most of the drugs are having *Tikta*, *Kashaya Rasa*, *Ushna Virya Laghu*, *Ruksha Guna* and *Vata hara* properties which helps in alleviating the diseases of *Vata*. Also, it acts as *Amapachana* and removes the *Avarana* of *Kaphadi Dosha*. Drugs like *Gambhari*, *Gokshura*, *Brihati*, and possess properties such as *Garbhashaya Shodhaka* which helps during pregnancy and restores energy in women after delivery. Drugs having *Shothahara* properties help to alleviate *Shotha* associated with *Vata* disorder.

Katuki

Katuki has been widely known and used as hepatoprotective agent. In liver injury mainly kuffer cells cause problems in regeneration process and it here when extract of this plant plays its role by supporting cells. This plant has been currently used in treating liver disease, viral hepatitis, ischemic injury, cirrhosis, radiation toxicity.

Sathapushpa Churna

Shatapushpa have *Katu*, *Tikta* and *Madhura Rasa*. *Katu Rasa* has *Agneya* properties and *Tikta Rasa* has *Deepan* properties, which improve *Jathragni Daurbalya* and from *Nirama Rasa Dhatu* and helps in *Artavkshaya*. *Tikta Rasa* also has *Lekhana* properties due to this it work on *Avarana* and improve *Picchila* and *Kleda* properties of *Kapha Dosha*. *Ushna Virya* of *Shatapushpa* removes *Srotoavarodha* and increase the blood circulation in the *Yoni* and *Garbhashaya*, due to this *Garbhashaya* gets proper nutrition which helps formation of healthy endometrium and thus menstrual cycle become normal in amount, duration and interval.

[10]

Kanchanar Guggulu

Kanchanar Guggulu is an effective *Ayurvedic* classical preparation that helps to promote a fully mature ovum and reduce the chance of PCOS. According to *Ayurveda* the aggravation of *Kapha* and *Mandagni* is considered responsible for PCOS. Its effective *Ayurvedic* remedy for treating hormonal imbalance, hypothyroidism, PCOS, and joint pain.

Pathadi Kwatha

Amapachaka, *Srotoshodhana*, and *Vatakapha Nashaka* properties responsible for efficacy. *Usna*, *Tikshna Lekhana* and *Pachana* etc. properties of contents of *Pathadi Kwatha* are similar to *Pitta* increase *Anegya Guna* of *Pitta* which is responsible for decreasing interval.

Conclusion

As the PCOS is multi-faceted problem with reproductive, endocrine and metabolic dysfunction. The lifestyle modification, counseling and various *Ayurveda* medications is considered to be the first line of treatment which is effective in reducing the sign and symptoms of PCOS. In above explained case, her menstrual irregularity and other associated symptoms became normal with *Ayurveda* medication and *Nasya* in 3 month which is very positive. However, a well-planned study with large sample size is required to establish the efficacy of *Ayurveda* in PCOS.

References

1. Konar H. D. C. Dutta's textbook of gynecology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; Chapter 29. p.384 [Crossref][PubMed][Google Scholar]
2. Riley DS, Barber MS, Kienle GS, Aronson JK, von Schoen-Angerer T, Tunwell P, et al. CARE guideline for case reports: explanation and elaboration document. J Clin Epidemiol. 2017 Sep 1;89:218–35. [Crossref][PubMed][Google Scholar]
3. Dhandapani K, Kodavanji B, Anantharaya VN, Kumar NA. Prevalence and distribution of causes of infertility according to women's age: a cross-sectional study in a tertiary healthcare hospital setup. J Basic Clin Physiol Pharmacol. 2021 Jun 29. [Crossref][PubMed][Google Scholar]

4. Kiconco S, Teede HJ, Azziz R, Norman RJ, Joham AE. The need to reassess the diagnosis of polycystic ovary syndrome: a review of diagnostic recommendations from the international evidence-based guideline for the assessment and management of PCOS. *Semin Reprod Med.* 2021 Aug 17. *New York: Thieme Medical Publishers* [Crossref][PubMed][Google Scholar]
 5. Fulghesu AM, Piras C, Dessi A, Succu C, Atzori L, Pintus R, et al. Urinary metabolites reveal hyperinsulinemia and insulin resistance in polycystic ovarian syndrome. *Metabolites.* 2021 Jul;11(7):437. [Crossref][PubMed][Google Scholar]
 6. Diamanti-Kandarakis E, Kandarakis H, Legro RS. The role of genes and environment in the etiology of PCOS. *Endocrine.* 2006 Aug;30(1):19–26. [Crossref][PubMed][Google Scholar]
 7. Hart R, Doherty DA. The potential implications of a PCOS diagnosis on women's long-term health using data linkage. *J Clin Endocrinol Metab.* 2015 Mar 1;100(3):911–9. [Crossref][PubMed][Google Scholar]
 8. Chaudhary A. Clinical treatment of polycystic ovary syndrome. in *Ayurveda.* . [Crossref][PubMed][Google Scholar]
 9. Ghatwate RB. A case report on Ayurveda management of polycystic ovarian syndrome (PCOS). *World J Pharm Pharm Sci.* 2020;9(11):1810–5. [Crossref][PubMed][Google Scholar]
 10. Barbieri RL. Polycystic ovarian disease. *Annu Rev Med.* 1991 Feb;42(1):199–204. [Crossref][PubMed][Google Scholar]
 11. Nehara H. Ayurveda and modern perspective on polycystic ovarian syndrome: a review based on literary study. *Himal J Health Sci.* 2019 Jul 16;1(1):9–12. [Crossref][PubMed][Google Scholar]
 12. Rath P. Management of PCOS through homoeopathy. a case report. . [Crossref][PubMed][Google Scholar]
 13. Magotra A. Management of PCOD w. s. r. to *Ayurvedic drugs and lifestyle.* *J Ayurveda Integr Med Sci.* 2020 Oct 31;5(5):287–9 [Crossref][PubMed][Google Scholar]
 14. International Journal of Pharmaceutical Research and Application. 2023 Jul–Aug. 8(4):989–97. . [Crossref][PubMed][Google Scholar]
 15. Goyal S, Rath S. A comprehensive review of Jatamansi. *Int J Res Ayush Allied Syst.* . [Crossref][PubMed][Google Scholar]
 16. Kathoke MH, et al. PCOS: management of PCOS. *World J Pharm Med Res.* . [Crossref][PubMed][Google Scholar]
 17. Sharma P, et al. Yoga—a safe and effective treatment for PCOS: an Ayurvedic review. *World J Pharm Med Res.* 2021;7(10). [Crossref][PubMed][Google Scholar]
 18. Ghatwate RB. A case report on Ayurveda management of polycystic ovarian syndrome (PCOS). *World J Pharm Pharm Sci.* 2020;9(11):1810–5. [Crossref][PubMed][Google Scholar]
 19. Muhas C, Nishad KM, Ummunnoora KP, Jushna K, Saheera KV, Dilsha KP. Polycystic ovary syndrome—an overview. *Int J Curr Pharm Res.* 2018;10(6). [Crossref][PubMed][Google Scholar]
 20. Tasoula T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. *Clin Endocrinol (Oxf).* 2004;60:1–17. [Crossref][PubMed][Google Scholar]
- Disclaimer / Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of Journals and/or the editor(s). Journals and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.